Abstract:Ethnopharmacological evidenceThe anti-inflammatory effect of Dan-Lou tablets (DLT) have been reported; however, the signaling pathways involved and their role in foam cell formation remains unclear.Aim of the studyThe purpose of this study was to determine the molecular target and mechanism of DLT in the treatment of coronary heart disease (CHD), and investigate the role of DLT in inhibiting foam cell formation and the anti-inflammatory effects of RAW 264.7 macrophages.Materials and methodsThis study explored and elucidated the main active components, therapeutic targets, and pharmacological mechanisms of DLT treatment for CHD using network pharmacology. Secondly, the accuracy of the interaction of key active compounds with key proteins was verified by molecular docking analysis. Eight chemical compositions were determined from the ethanol extract of DLT (EEDL) by high-performance liquid chromatography. Finally, this study used EEDL intervention with oxidized low-density lipoprotein (ox-LDL) to induce RAW264.7 macrophages to verify the results of network pharmacology.ResultsAccording to network pharmacological analysis, 269 common targets of DLT and CHD were obtained from an online database, and 24 key targets were obtained from further analysis. GO enrichment and KEGG analyses were performed, mainly involving the cAMP, cGMP-PKG, MAPK, and NF-κB signaling pathways, and vascular smooth muscle contraction. Molecular docking showed that the active components in DLT docked well with MyD88, NF-κB, and p38 MAPK. The eight compounds from the EEDL have been identified as gallic acid, salvianolic acid, puerarin, daidzein, paeoniflorin, salvianolic acid B, cryptotanshinone, and tanshinone IIA with concentrations of 4.62, 4.76, 23.73, 34.24, 14.59, 21.69, 0.34, and 0.47 μg/mg, respectively. Further in vitro experiments showed that the levels of MyD88 and p-p38 MAPK in RAW 264.7 macrophages induced by ox-LDL increased noticeably. Stimulating the NF-κB signaling pathway increased the release of pro-flammatory factors (TNF-α and IL-1β) and strengthened the inflammatory response (P < 0.05 or P < 0.01), while the levels of MyD88, p38 MAPK, NF-κB, TNF-α, and IL-1β decreased after EEDL treatment (P < 0.05 or P < 0.01).ConclusionThe study demonstrated that the anti-inflammatory activity of the DLT intervention of ox-LDL-induced RAW 264.7 macrophages may involve the MyD88/p38 MAPK/NF-κB signaling pathway.

A Novel Compound DSC Suppresses Lipopolysaccharide-Induced Inflammatory Responses by Inhibition of Akt/NF-κB Signalling in Macrophages

Inhibition of Nuclear Factor Kappa B As a Mechanism of Danshensu During Toll-like Receptor 2-Triggered Inflammation in Macrophages.

Effect of Danshen on TLR2-triggered inflammation in macrophages

A Novel Danshensu Derivative Ameliorates Experimental Colitis by Modulating NADPH Oxidase 4‐dependent NLRP3 Inflammasome Activation

Salvianic Acid A Inhibits Induction of Inflammatory Mediators by Blocking Nuclear Factor-κB Activation in Macrophages

A Novel Compound Derived from Danshensu Inhibits Apoptosis Via Upregulation of Heme Oxygenase-1 Expression in SH-SY5Y Cells

A Novel Derivative of the Natural Product Danshensu Suppresses Inflammatory Responses to Alleviate Caerulein-Induced Acute Pancreatitis

Molecular Weight-Dependent Immunostimulative Activity Of Low Molecular Weight Chitosan Via Regulating Nf-Kappa B And Ap-1 Signaling Pathways In Raw264.7 Macrophages

A CRTH2 Antagonist, CT-133, Suppresses NF-κB Signalling to Relieve Lipopolysaccharide-Induced Acute Lung Injury.

Anti-inflammatory Effects of Ganoderma Lucidum Sterols Via Attenuation of the P38 MAPK and NF-κB Pathways in LPS-induced RAW 264.7 Macrophages

Dan-Lou tablets reduces inflammatory response via suppression of the MyD88/p38 MAPK/NF-κB signaling pathway in RAW 264.7 macrophages induced by ox-LDL

(7R,8s)-9-acetyl-dehydrodiconiferyl Alcohol Inhibits Inflammation and Migration in Lipopolysaccharide-Stimulated Macrophages

Pinus densiflora needle supercritical fluid extract suppresses the expression of pro-inflammatory mediators iNOS, IL-6 and IL-1β, and activation of inflammatory STAT1 and STAT3 signaling proteins in bacterial lipopolysaccharide-challenged murine macrophages

Compound FLZ Inhibits Lipopolysaccharide-Induced Inflammatory Effects Via Down-Regulation of the TAK-IKK and TAK-JNK/p38MAPK Pathways in RAW264.7 Macrophages.

Diallyl disulfide suppresses the lipopolysaccharide-driven inflammatory response of macrophages by activating the Nrf2 pathway

Glucocorticoid receptor agonist compound K regulates Dectin-1-dependent inflammatory signaling through inhibition of reactive oxygen species

(7 R ,8 S )-Dehydrodiconiferyl Alcohol Suppresses Lipopolysaccharide-Induced Inflammatory Responses in BV2 Microglia by Inhibiting MAPK Signaling

Daphnetin Reduces Endotoxin Lethality in Mice and Decreases LPS-induced Inflammation in Raw264.7 Cells Via Suppressing JAK/STATs Activation and ROS Production

Protective Effect of Membrane-Free Stem Cells against Lipopolysaccharide and Interferon-Gamma-Stimulated Inflammatory Responses in RAW 264.7 Macrophages

Design and Synthesis Novel Di-Carbonyl Analogs of Curcumin (dacs) Act As Potent Anti-Inflammatory Agents Against LPS-induced Acute Lung Injury (ALI)

Schisandrin A suppresses lipopolysaccharide-induced inflammation and oxidative stress in RAW 264.7 macrophages by suppressing the NF-κB, MAPKs and PI3K/Akt pathways and activating Nrf2/HO-1 signaling